article Open AccessTop 1% cited

Revised Response Criteria for Malignant Lymphoma

Journal of Clinical Oncology · 2007 · Vol. 25(5) · pp. 579–586

Abstract

We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

Lymphoma Diagnosis and Treatment Lung Cancer Treatments and Mutations CNS Lymphoma Diagnosis and TreatmentMedicineMedical physicsHarmonizationLymphomaPositron emission tomographyClinical trialOncologyInternal medicineNuclear medicine

MeSH terms

Clinical Trials as TopicFlow CytometryHodgkin DiseaseHumansImage Interpretation, Computer-AssistedImmunohistochemistryLymphoma, Non-HodgkinTerminology as TopicTime FactorsTomography, X-Ray ComputedSurvival AnalysisTreatment OutcomeRadiopharmaceuticalsFluorodeoxyglucose F18Endpoint Determination

Citations

4,425

FWCI

102.81

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Positron Emission Tomography (PET) in Oncology